Correlation between DNA Methylation and Cell Proliferation Identifies New Candidate Predictive Markers in Meningioma.

Fiche publication

Date publication

décembre 2022

Journal

Cancers

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GAUCHOTTE Guillaume , Dr BATTAGLIA-HSU Shyue-Fang , Dr RECH Fabien

Tous les auteurs :
Hergalant S, Saurel C, Divoux M, Rech F, Pouget C, Godfraind C, Rouyer P, Lacomme S, Battaglia-Hsu SF, Gauchotte G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36551712

Résumé

Meningiomas are the most common primary tumors of the central nervous system. Based on the 2021 WHO classification, they are classified into three grades reflecting recurrence risk and aggressiveness. However, the WHO's histopathological criteria defining these grades are somewhat subjective. Together with reliable immunohistochemical proliferation indices, other molecular markers such as those studied with genome-wide epigenetics promise to revamp the current prognostic classification. In this study, 48 meningiomas of various grades were randomly included and explored for DNA methylation with the Infinium MethylationEPIC microarray over 850k CpG sites. We conducted differential and correlative analyses on grade and several proliferation indices and markers, such as mitotic index and Ki-67 or MCM6 immunohistochemistry. We also set up Cox proportional hazard models for extensive associations between CpG methylation and survival. We identified loci highly correlated with cell growth and a targeted methylation signature of regulatory regions persistently associated with proliferation, grade, and survival. Candidate genes under the control of these regions include , , , , , , and --, i.e., the protocadherin gene clusters. This study highlights the crucial role played by epigenetic mechanisms in shaping dysregulated cellular proliferation and provides potential biomarkers bearing prognostic and therapeutic value for the clinical management of meningioma.